Document is current

Article History

Received: 30 May 2025

Revised: 31 August 2025

Accepted: 18 September 2025

First Online: 24 November 2025

Change Date: 27 January 2026

Change Type: Update

Change Details: The correct affiliation for professor Prithviraj Bose is: 5 Department of Leukemia, University of Texas MD Anderson Cancer Center. Prithviray Bose’s affiliation was erroneously reported as “5Wake Forest University School of Medicine, Winston Salem, NC, USA.”

Competing interests

: MM was a consultant to Gilead, Novartis, Roche, Menarini, and GSK. MM received support for meeting participation from AbbVie and Roche. MM is a member of The Methodology Team for Guideline Development of the Italian Society of Hematology and a PLOS-ONE Academic Associate Editor. AMV received speaker honoraria from Incyte, AbbVie, Novartis, BMS, AOP, ITF, and participated in Safety or Advisory Boards for Incyte, Novartis, and BMS. JM received grants from Incyte, Novartis, AbbVie, BMS, CTI/SOBI, Karyopharm, Geron, Kartos, and PharmaEssentia and consulting fees from Incyte, Novartis, AbbVie, BMS, CTI/SOBI, Karyopharm, Geron, Kartos, Roche, Mark, GSK, Disc, PharmEssentia, MorphoSys, and Keros. AAL received honoraria for lectures from AOP and GSK and consulting fees from AOP. PB received grants from Incyte, BMS, CTI/SOBI, Morphosys, Kartos, telios, Janssen, Geron, Ionis, Disc, Karyopharm, Sumitomo, Ajax, Blueprint, Cogent, and consulting fees from Incyte, BMS, CTI/SOBI, GSK, AbbVie, Morphosys, PharaEssentia, Ionis, Disc, Karyopharm, Sumitomo, Geron, Morphic, Jubilant, Keros, Ono, Raythera, Novartis, Blueprint, Cogent. RPG is a consultant to Antengene Biotech LLC; Medical Director, FFF Enterprises Inc.; A speaker for Janssen Pharma and Hengrui Pharma; Board of Directors: Russian Foundation for Cancer Research Support and Scientific Advisory Board, StemRad Ltd. CH received consulting fees from Sobi, Merck, GSK, OPNA Bio, Incyte, BMS, Alethiomics, CTI, Silence Therapeutics, Karyopharm, Galecto, Mennari Stemline, DISC, Keros, Morphosys, Novartis. CH also received honoraria for lectures from Novartis, GSK, Merck, Menarini Stemline, AOP, BMS, Incyte, Morphosys, and support for attending meetings from Novartis. CH disclaims her leadership role for MPN Voice and Blood Cancer UK. RH does not disclose any COI. JJK participated in Safety or Advisory Boards for Incyte and BMS and received support for meeting attendance from Novartis. JJK received honoraria as a speaker from AOP and PharmaEssenti and consulting fees from GSK, Novartis, and AbbVie. Gilead, Jazz, Omeros, Sanofi, Italfarmaco. SK received consulting fees from Novartis, BMS, Incyte /Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Karthos, Sierra Oncology, Glaxo-Smith Kline (GSK), Imago Biosciences, AbbVie, MSD, iOMEDICO. SK also received speaker honoraria from Novartis, BMS, Pfizer, Incyte, Ariad, Shire, Roche, AOP Pharma, Janssen, Geron, Celgene, Karthos, AbbVie, iomedico, GSK, MSD, and payment for expert testimony from Novartis and GSK. SK received support for meeting attendance from Alexion, Novartis, BMS, Celgene, Incyte, Ariad, AOP Pharma, CTI, Pfizer, Sanofi, Janssen, Geron, Imago Biosciences, GSK, PharmaEssentia, Sierra, Oncology, AbbVie, iOMEDICO, and MSD. SK has a patent for a BET inhibitor drug for RWTH Aachen University. SK joined Safety or Advisory Boards for Pfizer, Incyte/Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, MPN Hub, Sierra Oncology, Glaxo-Smith Kline, and AbbVie. SK is Chairman of the Hemostasis Working Party of German Society of Hematology and Medical Oncology (DGHO), Speaker of German Study Group of MPN (GSG-MPN), Member of Guidelines Committee of European Haematology Association (EHA), and Associate Editor for Hemasphere journal. RM did not disclose any COI. FP received honoraria for lectures from Novartis, Bristol-Myers, Squibb, Abbvie, GSK, Janssen, AOP Orphan, Novartis, Bristol-Myers, Squibb, AbbVie, GSK, Janssen, AOP Orphan, and Jazz. FP also participated in Safety Monitoring Boards or Advisory Boards for Novartis, Bristol-Myers, Squibb/ Celgene, GSK, AbbVie, AOP Orphan, Janssen, Sumitomo, and Kartos. AR participated in Safety Monitoring Boards or Advisory Boards for Amgen, Novartis, and Kite. AT did not disclose any COI. TB did not disclose any COI.

: Ethics approval was not needed since patients’ data were not managed, nor tests or treatments performed.